Parkinson's disease is a chronic, progressive neurological disorder that results from the degeneration of neurons in a region of the brain that controls movement. Parkinson's disease is characterized by a number of symptoms including tremors, limb stiffness, slowness of movements, and difficulties with posture and balance with severity tending to worsen over time.

In the United States, it is estimated that 60,000 new cases are diagnosed each year, joining the 1.5 million Americans who currently have Parkinson's disease. While the condition usually develops after the age of 65, 15% of those diagnosed are under 50.

Parkinson's Programs

SPN803:

• Supernus is pursuing a novel PK profile and dosing schedule designed to improve therapy and reduce side effects.
  
• Phase I was completed in 2008.
  
• QD dosing for SPN803 vs TID dosing for reference product has been demonstrated.